Marisa Dolled‐Filhart

Merck & Co., Inc., Rahway, NJ, USA (United States)

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial”.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet(2016)10.1016/s0140-6736(15)01281-7

N/A

1.3DataRank · unranked

6497 citations

Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han +20 more

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

UNC Libraries(2020)10.17615/29f0-zz17

N/A

0DataRank · unranked

0 citations

M. T. Goodman, Nilanjan Chatterjee, W. F. Anderson, R. K. Matsuno, Charles M. Perou +10 more